RevenanasBook a free audit

Signal

Phathom Pharmaceuticals Q3 2026: $84.7M Revenue, 380,000 VOQUEZNA Prescriptions

October 29, 2026

Biotech

Signal

Key Facts

Signal Type

Signal

Industry

Biotech

Companies

Phathom Pharmaceuticals Inc

Date

October 29, 2026

Key Earnings Metrics

Phathom Pharmaceuticals Inc earnings snapshot
MetricReportedContext
Q3 2026 Net Revenue$84.7MThird quarter 2026 net revenues
VOQUEZNA Prescriptions380,000Total prescriptions filled in Q3 2026
Covered Prescriptions248,00065% of total, up 19% sequentially
Cash-Pay Prescriptions132,000Up 6% sequentially in Q3 2026

Phathom Pharmaceuticals delivered its strongest quarter yet for VOQUEZNA, with revenue growth accelerating on both a year-over-year and sequential basis. The prescription mix continued shifting toward covered volume, which now accounts for nearly two-thirds of total scripts.

  • Q3 2026 Net Revenue: $84.7M. Up 71% from Q3 2025 and 14% from Q2 2026, reflecting both higher prescription volume and an improving covered-to-cash-pay ratio.
  • Total VOQUEZNA Prescriptions: 380,000. The combined covered and cash-pay volume for the quarter, representing continued quarterly growth in absolute script counts.
  • Covered Prescriptions: 248,000. Accounting for 65% of total prescriptions, covered volume grew 19% sequentially, pointing to broader payer acceptance.
  • Cash-Pay Prescriptions: 132,000. Up 6% sequentially, showing that even as covered volume expands, the cash-pay channel continues to grow at a modest pace.
  • Sequential Revenue Growth: 14%. The quarter-over-quarter increase from Q2 2026 to Q3 2026 demonstrates sustained commercial momentum beyond the year-over-year base effect.

The covered prescription growth rate of 19% sequentially outpaced the cash-pay growth rate of 6%, meaning the mix is tilting toward insured patients. That matters because covered prescriptions typically carry higher net revenue per script and greater patient persistence over time.

Revenue growing 14% sequentially while covered scripts grew 19% suggests that the covered channel is becoming the primary revenue driver. If this trend holds, Phathom's revenue base becomes less dependent on cash-pay volume, which can be more volatile and price-sensitive.

Management Commentary

Phathom did not provide formal guidance for the quarter. The company's disclosed commentary focused on the commercial execution of VOQUEZNA and the introduction of the BlinkRx copay program.

Management highlighted the new copay offering through BlinkRx, which allows eligible commercially insured patients to pay as little as $0 for VOQUEZNA. This program is designed to reduce out-of-pocket costs and improve adherence for patients with commercial insurance.

The BlinkRx initiative directly addresses one of the most common barriers to prescription persistence: copay burden. By lowering the effective patient cost, Phathom is attempting to convert more commercially insured patients into long-term VOQUEZNA users rather than one-time fills.

Management's emphasis on the copay program rather than guidance or pipeline updates suggests the company's near-term focus is squarely on commercial penetration and access expansion. The priority appears to be maximizing VOQUEZNA's uptake in the acid-related disorder market.

Strategic Implications

The 71% year-over-year revenue growth establishes that VOQUEZNA is gaining real commercial traction, not just incremental adoption. A $84.7 million quarterly revenue figure puts Phathom on a pace that, if sustained, would exceed $300 million in annualized revenue.

The covered prescription mix reaching 65% is a meaningful inflection point. When a specialty pharmaceutical product crosses the two-thirds covered threshold, it typically means payer formulary access has moved beyond early adopters and into broader acceptance. This reduces the risk of sudden prescription declines due to coverage denials.

The BlinkRx copay program could accelerate the covered mix further. If commercially insured patients can access VOQUEZNA at $0 out-of-pocket, the incentive to remain on therapy improves substantially. This is particularly relevant for chronic conditions where patients may otherwise discontinue treatment after initial symptom relief.

Cash-pay prescriptions still growing at 6% sequentially is worth noting. It indicates that even without insurance coverage, demand for VOQUEZNA exists at the cash price point. This provides a floor under prescription volume and suggests the product has genuine patient demand beyond what payer access alone would generate.

The 14% sequential revenue growth, when combined with the 19% sequential covered script growth, implies that revenue per covered prescription is relatively stable. There is no evidence of significant pricing erosion or channel mix distortion in the quarter. The growth appears volume-driven rather than price-driven.

For revenue leaders watching this quarter, the key structural shift is the covered-to-cash-pay ratio. In Q3 2026, covered scripts grew three times faster than cash-pay scripts. If this ratio continues, Phathom's revenue profile becomes more predictable and less exposed to cash-pay churn risk.

The absence of formal guidance limits visibility into management's internal expectations. However, the disclosed strategic action around BlinkRx signals confidence that prescription growth can continue without additional pipeline catalysts in the near term.

What to Watch Next

I would watch four things over the next two quarters:

  • Covered prescription mix. If covered scripts move above 70% of total volume, it would confirm that payer access is broadening beyond initial formulary wins and into mainstream acceptance.
  • BlinkRx copay adoption rate. The number of commercially insured patients using the $0 copay program will reveal whether the initiative is converting intent into actual prescription fills and refills.
  • Cash-pay prescription trajectory. If cash-pay volume flattens or declines while covered volume continues growing, it would indicate that patients are migrating from cash-pay to covered status rather than the market expanding overall.
  • Sequential revenue growth sustainability. Maintaining double-digit sequential growth in Q4 2026 would demonstrate that the Q3 acceleration was not a one-quarter anomaly driven by seasonal or one-time factors.

The covered prescription growth is the most important structural metric to track. A product that moves from majority cash-pay to majority covered over several quarters typically experiences a step-change in revenue durability, because covered patients refill at higher rates and are less price-sensitive at the point of sale.

The BlinkRx copay program is the most important strategic initiative to monitor. If it drives measurable increases in commercially insured prescription volume in Q4 2026, it validates the thesis that out-of-pocket cost has been the primary barrier to broader VOQUEZNA adoption.

Without formal guidance, the market will rely on prescription-level data to assess whether the 71% year-over-year growth rate can be sustained. A deceleration to 40-50% year-over-year growth would still be strong but would signal that the initial launch curve is maturing.

Phathom's Q3 2026 results show a company whose commercial execution is improving on the metrics that matter most for a launched specialty pharmaceutical: volume, payer access, and patient affordability. The next two quarters will test whether that improvement is structural or cyclical.

Source: EarningsPrism (earningsprism.com)

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner